For the benefit of patients

We are a commercial stage biopharmaceutical company, focused on the development of products that address the medical challenges in the therapeutic areas of oncology and anti-infectives.

For the benefit of patients

We are a commercial stage biopharmaceutical company, focused on the development of products that address the medical challenges in the therapeutic areas of oncology and anti-infectives.

We are committed to discovering, developing and commercializing innovative pharmaceutical products to meet the medical needs of patients with serious and life-threatening conditions. Basilea is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN).

CEO David Veitch | Full-year 2020 Update

Play

News

Jul 14. 2021 / Ad hoc announcement

Basilea announces distribution agreement with JSC Lancet for antibiotic Zevtera® (ceftobiprole) covering Russia and the Eurasian Economic Union

Jun 07. 2021

Basilea reports new prevalence data for EB1, a potential response-predictive biomarker for lisavanbulin in glioblastoma and other tumor types, at ASCO Annual Meeting

May 31. 2021

Basilea provides updates on efficacy data with derazantinib in bile duct cancer and on ongoing clinical programs in urothelial and gastric cancer

May 19. 2021

Basilea awarded CARB-X grant of up to USD 2.7 million to develop novel-class antibiotic

News Archive

Annual Report 2020

Download English
Download German (short version)

Report Archive

CEO Statement

For the benefit of patients around the world, we are continuing to establish Cresemba and Zevtera as truly global brands. In addition, by strengthening our pre-clinical and clinical oncology pipeline, we aim to become a leading provider of innovative cancer therapies in the future.

Facts & Figures

Located in the heart of the life-sciences hub Basel

Play